Stifel Nicolaus Trims Teladoc Health (NYSE:TDOC) Target Price to $16.00

Teladoc Health (NYSE:TDOC) had its target price cut by Stifel Nicolaus from $21.00 to $16.00 in a research report report published on Friday morning, Benzinga reports. They currently have a hold rating on the health services provider’s stock.

Several other research analysts have also recently issued reports on the company. Barclays reduced their price objective on Teladoc Health from $25.00 to $20.00 and set an overweight rating for the company in a research note on Friday. Leerink Partnrs reissued a market perform rating on shares of Teladoc Health in a report on Monday, February 26th. Truist Financial decreased their target price on Teladoc Health from $23.00 to $17.00 and set a hold rating on the stock in a research report on Wednesday, March 6th. DA Davidson reduced their price objective on Teladoc Health from $22.00 to $18.00 and set a neutral rating on the stock in a research report on Wednesday, February 21st. Finally, Piper Sandler reduced their price objective on Teladoc Health from $30.00 to $25.00 and set an overweight rating on the stock in a research report on Wednesday, February 21st. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of Hold and a consensus price target of $19.67.

Teladoc Health Trading Down 2.4 %

Shares of Teladoc Health stock opened at $13.01 on Friday. Teladoc Health has a 52 week low of $12.65 and a 52 week high of $30.41. The company has a quick ratio of 3.47, a current ratio of 3.54 and a debt-to-equity ratio of 0.66. The stock’s fifty day moving average is $15.01 and its two-hundred day moving average is $17.77.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings data on Thursday, April 25th. The health services provider reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02). Teladoc Health had a negative return on equity of 10.11% and a negative net margin of 8.90%. The company had revenue of $646.13 million for the quarter, compared to analysts’ expectations of $637.31 million. During the same quarter last year, the company earned ($0.37) earnings per share. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. Sell-side analysts predict that Teladoc Health will post -1.07 earnings per share for the current fiscal year.

Insider Activity

In other news, CTO Nikolaos P. Nanis sold 2,866 shares of Teladoc Health stock in a transaction on Monday, March 4th. The stock was sold at an average price of $14.52, for a total value of $41,614.32. Following the completion of the sale, the chief technology officer now directly owns 69,850 shares of the company’s stock, valued at $1,014,222. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Jason N. Gorevic sold 53,755 shares of the company’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $780,522.60. Following the completion of the transaction, the chief executive officer now directly owns 653,073 shares of the company’s stock, valued at approximately $9,482,619.96. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CTO Nikolaos P. Nanis sold 2,866 shares of the company’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.52, for a total value of $41,614.32. Following the transaction, the chief technology officer now directly owns 69,850 shares of the company’s stock, valued at $1,014,222. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 135,441 shares of company stock valued at $2,038,251. 1.63% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TDOC. Vanguard Group Inc. lifted its holdings in shares of Teladoc Health by 11.8% in the 4th quarter. Vanguard Group Inc. now owns 17,515,127 shares of the health services provider’s stock valued at $377,451,000 after purchasing an additional 1,855,480 shares during the last quarter. ARK Investment Management LLC raised its stake in Teladoc Health by 4.5% during the 4th quarter. ARK Investment Management LLC now owns 21,224,565 shares of the health services provider’s stock valued at $457,389,000 after acquiring an additional 912,692 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Teladoc Health by 25.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,834,422 shares of the health services provider’s stock valued at $82,636,000 after acquiring an additional 767,999 shares during the last quarter. Norges Bank purchased a new stake in Teladoc Health during the 4th quarter valued at approximately $9,714,000. Finally, Charles Schwab Investment Management Inc. raised its stake in Teladoc Health by 37.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,549,585 shares of the health services provider’s stock valued at $28,807,000 after acquiring an additional 418,909 shares during the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.